Buchumschlag

PerSurge (NOA-30) phase II trial of perampanel treatment around surgery in patients with progressive glioblastoma

Glioblastoma is the most frequent and a particularly malignant primary brain tumor with no efficacy-proven standard therapy for recurrence. It has recently been discovered that excitatory synapses of the AMPA-receptor subtype form between non-malignant brain neurons and tumor cells. This neuron-tumo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Heuer, Sophie (VerfasserIn) , Burghaus, Ina (VerfasserIn) , Gose, Maria (VerfasserIn) , Keßler, Tobias (VerfasserIn) , Sahm, Felix (VerfasserIn) , Vollmuth, Philipp (VerfasserIn) , Venkataramani, Varun (VerfasserIn) , Hoffmann, Dirk C. (VerfasserIn) , Schlesner, Matthias (VerfasserIn) , Ratliff, Miriam (VerfasserIn) , Hopf, Carsten (VerfasserIn) , Herrlinger, Ulrich (VerfasserIn) , Ricklefs, Franz Lennard (VerfasserIn) , Bendszus, Martin (VerfasserIn) , Krieg, Sandro (VerfasserIn) , Wick, Antje (VerfasserIn) , Wick, Wolfgang (VerfasserIn) , Winkler, Frank (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 26 January 2024
In: BMC cancer
Year: 2024, Jahrgang: 24, Heft: 1, Pages: 1-13
ISSN:1471-2407
DOI:10.1186/s12885-024-11846-1
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s12885-024-11846-1
Verlag, kostenfrei, Volltext: https://bmccancer.biomedcentral.com/articles/10.1186/s12885-024-11846-1
Verlag, kostenfrei, Volltext: https://pmc.ncbi.nlm.nih.gov/articles/PMC10811925
Volltext
Verfasserangaben:Sophie Heuer, Ina Burghaus, Maria Gose, Tobias Kessler, Felix Sahm, Philipp Vollmuth, Varun Venkataramani, Dirk Hoffmann, Matthias Schlesner, Miriam Ratliff, Carsten Hopf, Ulrich Herrlinger, Franz Ricklefs, Martin Bendszus, Sandro M. Krieg, Antje Wick, Wolfgang Wick, Frank Winkler
Beschreibung
Zusammenfassung:Glioblastoma is the most frequent and a particularly malignant primary brain tumor with no efficacy-proven standard therapy for recurrence. It has recently been discovered that excitatory synapses of the AMPA-receptor subtype form between non-malignant brain neurons and tumor cells. This neuron-tumor network connectivity contributed to glioma progression and could be efficiently targeted with the EMA/FDA approved antiepileptic AMPA receptor inhibitor perampanel in preclinical studies. The PerSurge trial was designed to test the clinical potential of perampanel to reduce tumor cell network connectivity and tumor growth with an extended window-of-opportunity concept.
Beschreibung:Gesehen am 17.01.2024
Beschreibung:Online Resource
ISSN:1471-2407
DOI:10.1186/s12885-024-11846-1

Ähnliche Einträge